Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-02-07 Purchase |
2024-02-09 5:51 pm |
Adverum Biotechnologies Inc. | ADVM | Scopa James Paul Director |
100,000 | $1.35 | $135,000 | 103,334 (Indirect Direct) |
View |
| 2023-08-09 Sale |
2023-08-09 4:33 pm |
DICE Therapeutics Inc. | DICE | Scopa James Paul Director |
40,921 | $0 | $0 | 0 (Indirect Direct) |
View |
| 2023-03-17 Sale |
2023-03-21 4:47 pm |
DICE Therapeutics Inc. | DICE | Scopa James Paul Director |
10,000 | $29.05 | $290,500 | 45,841 (Indirect Direct) |
View |
| 2021-11-15 Sale |
2021-11-17 4:38 pm |
Adverum Biotechnologies Inc. | ADVM | Scopa James Paul Director |
50,000 | $2.18 | $109,000 | 3,334 (Indirect) |
View |
| 2021-09-15 Purchase |
2021-09-16 9:30 pm |
DICE Therapeutics Inc. | DICE | Scopa James Paul Director |
6,000 | $17 | $102,000 | 89,998 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2024-06-27 Option Award |
2024-06-28 4:07 pm |
N/A 2034-06-27 |
Aligos Therapeutics Inc. | ALGS | Scopa James Paul Director |
60,000 | $0 | 60,000 (Direct) |
View |
| 2024-06-17 Option Award |
2024-06-20 4:44 pm |
N/A 2034-06-16 |
Adverum Biotechnologies Inc. | ADVM | Scopa James Paul Director |
10,520 | $0 | 10,520 (Direct) |
View |
| 2024-02-28 Option Award |
2024-02-28 5:34 pm |
N/A 2031-04-26 |
Aligos Therapeutics Inc. | ALGS | Scopa James Paul Director |
8,823 | $0 | 8,823 (Direct) |
View |
| 2023-10-25 Option Award |
2023-10-27 4:13 pm |
2023-10-25 2030-10-25 |
Aligos Therapeutics Inc. | ALGS | Scopa James Paul Director |
91,541 | $0.125 | 274,624 (Direct) |
View |
| 2023-10-25 Option Award |
2023-10-27 4:13 pm |
N/A N/A |
Aligos Therapeutics Inc. | ALGS | Scopa James Paul Director |
183,083 | $0.7568 | 274,624 (Direct) |
View |
| 2023-08-02 Gift |
2023-08-03 7:37 pm |
N/A N/A |
DICE Therapeutics Inc. | DICE | Scopa James Paul Director |
2,420 | $0 | 40,921 (Indirect) |
View |
| 2023-07-20 Option Award |
2023-07-21 4:11 pm |
N/A 2033-07-20 |
Aligos Therapeutics Inc. | ALGS | Scopa James Paul Director |
20,000 | $0 | 20,000 (Direct) |
View |
| 2023-07-18 Gift |
2023-07-19 4:53 pm |
N/A N/A |
DICE Therapeutics Inc. | DICE | Scopa James Paul Director |
2,200 | $0 | 43,341 (Indirect) |
View |
| 2023-07-11 Gift |
2023-07-13 5:12 pm |
N/A N/A |
DICE Therapeutics Inc. | DICE | Scopa James Paul Director |
300 | $0 | 45,541 (Indirect) |
View |
| 2023-06-09 Option Award |
2023-06-13 5:17 pm |
N/A 2033-06-08 |
Adverum Biotechnologies Inc. | ADVM | Scopa James Paul Director |
40,000 | $0 | 40,000 (Direct) |
View |
| 2023-05-01 Gift |
2023-05-02 5:49 pm |
N/A N/A |
DICE Therapeutics Inc. | DICE | Scopa James Paul Director |
6,923 | $0 | 45,841 (Direct) |
View |
| 2022-10-24 Gift |
2023-03-21 4:47 pm |
N/A N/A |
DICE Therapeutics Inc. | DICE | Scopa James Paul Director |
30,719 | $0 | 45,841 (Direct) |
View |
| 2022-06-23 Option Award |
2022-06-27 4:13 pm |
N/A 2032-06-23 |
Aligos Therapeutics Inc. | ALGS | Scopa James Paul Director |
15,000 | $0 | 15,000 (Direct) |
View |
| 2022-06-10 Option Award |
2022-06-14 4:22 pm |
N/A 2032-06-09 |
Adverum Biotechnologies Inc. | ADVM | Scopa James Paul Director |
40,000 | $0 | 40,000 (Direct) |
View |
| 2022-06-07 Option Award |
2022-06-08 4:53 pm |
N/A 2032-06-06 |
DICE Therapeutics Inc. | DICE | Scopa James Paul Director |
21,250 | $0 | 21,250 (Direct) |
View |
| 2021-12-30 Ownership |
2022-02-11 5:33 pm |
N/A N/A |
DICE Therapeutics Inc. | DICE | Scopa James Paul Director |
3,000 | $0 | 55,841 (Direct) |
View |
| 2021-09-14 Option Award |
2021-09-16 9:30 pm |
N/A 2031-09-14 |
DICE Therapeutics Inc. | DICE | Scopa James Paul Director |
34,157 | $0 | 89,998 (Direct) |
View |
Ownership |
2021-09-14 7:34 pm |
N/A N/A |
DICE Therapeutics Inc. | DICE | Scopa James Paul Director |
0 | $0 | 69,000 (Direct) |
View |
| 2021-05-12 Option Award |
2021-05-14 8:03 pm |
N/A 2031-05-11 |
Adverum Biotechnologies Inc. | ADVM | Scopa James Paul Director |
40,000 | $0 | 40,000 (Direct) |
View |
| 2021-04-26 Option Award |
2021-04-27 4:42 pm |
N/A 2031-04-26 |
Aligos Therapeutics Inc. | ALGS | Scopa James Paul Director |
30,000 | $0 | 30,000 (Direct) |
View |
| 2020-06-23 Option Award |
2020-06-25 5:47 pm |
N/A 2030-06-22 |
Adverum Biotechnologies Inc. | ADVM | Scopa James Paul Director |
30,000 | $0 | 30,000 (Direct) |
View |
| 2020-05-04 Exercise |
2020-05-05 6:44 pm |
N/A 2029-04-30 |
Adverum Biotechnologies Inc. | ADVM | Scopa James Paul Director |
23,334 | $0 | 100,000 (Direct) |
View |
| 2020-05-04 Exercise |
2020-05-05 6:44 pm |
N/A N/A |
Adverum Biotechnologies Inc. | ADVM | Scopa James Paul Director |
23,334 | $6.48 | 100,000 (Indirect) |
View |